2021
A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome
Bloch MH, Landeros-Weisenberger A, Johnson JA, Leckman JF. A Phase-2 Pilot Study of a Therapeutic Combination of Δ9-Tetrahydracannabinol and Palmitoylethanolamide for Adults With Tourette’s Syndrome. Journal Of Neuropsychiatry 2021, 33: 328-336. PMID: 34340527, DOI: 10.1176/appi.neuropsych.19080178.Peer-Reviewed Original ResearchConceptsTourette syndromeTic symptomsUncontrolled trialsYale Global Tic Severity Scale-Total Tic ScoreDouble-blind placebo-controlled trialAvailable evidence-based treatmentsPhase 2 pilot studyExtension phasePlacebo-controlled trialRefractory Tourette syndromeTotal tic scoreEffective pharmacological treatmentCannabis-derived compoundsEvidence-based treatmentsTHC dosingSecondary outcomesPrimary outcomeComorbid conditionsPharmacological treatmentTic scoreYGTSS scoresTherapeutic combinationsSide effectsTrial designSyndrome
2019
Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome
Sukhodolsky DG, Walsh C, Koller WN, Eilbott J, Rance M, Fulbright RK, Zhao Z, Bloch MH, King R, Leckman JF, Scheinost D, Pittman B, Hampson M. Randomized, Sham-Controlled Trial of Real-Time Functional Magnetic Resonance Imaging Neurofeedback for Tics in Adolescents With Tourette Syndrome. Biological Psychiatry 2019, 87: 1063-1070. PMID: 31668476, PMCID: PMC7015800, DOI: 10.1016/j.biopsych.2019.07.035.Peer-Reviewed Original ResearchConceptsSupplementary motor areaYale Global Tic Severity ScaleFunctional magnetic resonanceTic Severity ScaleReal-time functional magnetic resonanceTourette syndromeSeverity ScaleYale Global Tic Severity Scale-Total Tic ScoreTotal tic scorePrimary outcome measureSham control conditionReduction of ticsMagnetic resonanceSecondary outcomesSessions of neurofeedbackCrossover studyTic symptomsTic scoreOutcome measuresMotor areaSecondary measuresTic severityReal neurofeedbackEnd pointNeurofeedback intervention
2018
A Systematic Review of Pharmacologic Treatments for School Refusal Behavior
Tobon A, Reed MO, Taylor JH, Bloch MH. A Systematic Review of Pharmacologic Treatments for School Refusal Behavior. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 368-378. PMID: 29741917, PMCID: PMC6909768, DOI: 10.1089/cap.2017.0160.Peer-Reviewed Original ResearchConceptsSchool refusalSystematic reviewPharmacologic treatmentFuture pharmacologic studiesSpecific psychosocial treatmentsLong-term outcomesNew pharmacologic agentsImportant pediatric problemSchool refusal behaviorComprehensive literature searchSignificant methodological limitationsImportant functional outcomesSecondary outcomesFunctional outcomeNewer antidepressantsPharmacologic trialsPharmacological treatmentPharmacologic agentsPharmacological interventionsPsychological interventionsPharmacologic studiesPsychosocial treatmentsMost trialsPediatric problemAnxiety symptoms
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2016
N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Yaffa A, Alvarenga PG, Jakubovski E, Mulqueen JM, Landeros-Weisenberger A, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Tourette Syndrome: Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of Child And Adolescent Psychopharmacology 2016, 26: 327-334. PMID: 27027204, PMCID: PMC6445198, DOI: 10.1089/cap.2015.0109.Peer-Reviewed Original ResearchConceptsBenefit of NACEfficacy of NACYale Global Tic Severity ScaleAttention-deficit/hyperactivity disorderObsessive-compulsive disorderTourette syndromeN-acetylcysteineObsessive-compulsive spectrum disordersSide effectsRecent placebo-controlled trialPediatric Tourette syndromePlacebo-controlled trialCurrent pharmacological treatmentsTreatment of ticsTotal tic scoreSeverity of ticsSubstantial side effectsTic Severity ScaleYears of ageMinimal side effectsPediatric TSPrimary outcomeSecondary outcomesGlutamatergic systemPharmacological treatment